Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal …
1. 系统已在2026-08-26 16:38:50对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
GY Liu, YF Ye, YF Jiang, GJ Chen, WX Xia, YS Huang…
Bmj, 2024
bmj.com
Objective To compare the effectiveness and safety of nab-paclitaxel, cisplatin, and capecitabine (nab-TPC) with gemcitabine and cisplatin as an alternative first line treatment option for recurrent or metastatic nasopharyngeal carcinoma. Design Phase 3, open label, multicentre, randomised trial. Setting Four hospitals located in China between September 2019 and August 2022. Participants Adults (≥ 18 years) with recurrent or metastatic nasopharyngeal carcinoma. Interventions Patients were randomised in a 1: 1 ratio to …
